Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs... see more

TSX:TH - Post Discussion

Theratechnologies Inc > Presentation is a good sign
View:
Post by SABBOBCAT on Jan 09, 2023 2:34pm

Presentation is a good sign

The fact they actually put up a new presentation very quickly into the new year vs. waiting to use the post earnings presentation is a healthy sign. Typically management would have likely sat on their hands and waited. This uncharacteristic effort tells me they are not only planning for the future but also are going to get out there and try to sell a story. The question is what are they trying to sell? An OO #2? Partnership? The whole enchilada? Only time will tell, but they are likely on a bit of a fishing expedition to see what they can get.

I'd like to think the shift was driven by a tap on the shoulder from large investors (Soleus?) and the BoD saying "enough is enough, time to drive value or we will find someone that can". And I don't think this is uniquely aimed at Paul. He is growing sales, but there is no flow through from any work to the share price. My guess is that if no value enhancing deal comes between now and May, Dubuc will be the one sent packing.

Comment by SPCEO1 on Jan 09, 2023 3:40pm
The timing of the enw presentation is almost certainly related totheir going to the JP Morgan Healthcare conference this week and meeting investors there.
Comment by SABBOBCAT on Jan 09, 2023 6:24pm
Did they announce they are going?
Comment by SPCEO1 on Jan 09, 2023 7:41pm
Since they are not making a formal presentation to the conference, they would not PR it. But almost all Healthcare companies are there every year - it is where deals get done.
Comment by Wino115 on Jan 10, 2023 10:36am
I wouldn't take the employee count as something that would get immediately reflected. It's definitely going to be a lagging indicator. But according to the Dec notes, that cost cutting was going to happen. Only way to do what they say they're doing. If he's saying EBITDA positive by year end and profitable beyond, he can only do it with a healthy dose of RD cuts and SGA cuts, plus ...more  
Comment by Trogarzon on Jan 10, 2023 11:10am
Shure hope something else than legacy products makes the stock move back above 2$.  It's a priority right now, otherwise they won't have the luxury of time to accomplish anything before shareholders decide it's time to do somthing about the stupid market cap.
Comment by scarlet1967 on Jan 10, 2023 11:41am
https://www.linkedin.com/posts/theratechnologies-inc_jpmorgan-sanfrancisco-biotech-activity-7018598564364722177-7cA5?utm_source=share&utm_medium=member_ios  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities